MIAMI, FL / ACCESSWIRE / June 29, 2015 / The newly formed team of Cheryl Shuman, MarijuanaStocks.com, and Wolf of Weed Street (the Team) are excited to announce the official launch of their first branded product, the ‘WolfShot.’ The Team has partnered with FBEC Worldwide Inc. (OTCPINK: FBEC) to bring to market this hemp based energy shot that not only tastes great but also has all the added benefits of hemp packed into an easy to carry 2 ounce bottle. The WolfShot’s proprietary blend boasts FDA approved and CFR-21 tested ingredients that no other energy drink on the market currently has. Consumers can inquire about free samples on www.wolfenergyshot.com, www.wolfofweedstreet.com, www.marijuanastocks.com, and www.fbecworldwideinc.com.

WolfShot holds a proprietary blend of herbal ingredients including hemp infused natural fruit extracts, probiotics, amino acids and caffeine. Typical energy drinks and caffeinated beverages can trigger spikes in blood sugar, stress levels and can even result in weight gain due to the metabolism of fat cells after consumption of traditional caffeine. FBEC Worldwide has agreements in place for exclusive use of the FDA approved new caffeine that would not only offer a healthier alternative but would make FBEC the only company allowed to make such claims with regard to the health impact of WolfShot. The exclusive formula that the company holds will also be protected from reverse engineering or being duplicated in any form.

Jason Spatafora (Wolf of Weed Street) stated, “I am excited to put my name and brand behind a product with such potential and one that I truly believe in. There is a huge market opportunity for hemp infused drinks in general and the energy shot market has proven to be extremely profitable, just ask 5 Hour Energy.”

Cheryl Shuman will be spearheading the PR efforts for the WolfShot and said, “Product placement and branding is one of my specialties. I have secured placements for products in FX’s Wilfred, CBS News, The New Ricki Lake Show, and much more. I am looking forward to getting behind a product with such an effective and unique formula.”

The Team will begin tapping into their vast networks utilizing and developing relationships to increase retail distribution and media exposure for the WolfShot. The Team anticipates the WolfShot to be revenue producing by August 2015.

Health Benefits of Hemp

-Hemp seeds are an incredible source of easily digested protein. They are vegan-friendly, and are the perfect alternative to those who are allergic to or dislike soy-based products. Hemp seeds also contain all 8 of the essential amino acids.

-Hemp seeds offer a great dose of healthy fats in an ideal ratio; 3:1 omega-6 to omega-3s. Hemp seeds also pack the Gamma Linolenic Acid (GLA) variety of omega-6 fats, which helps to build anti-inflammatory hormones up. These GLA fats can be exceptionally beneficial for those with diabetes, metabolism issues, infections, or stress.

-Hemp seeds have an abundance of disease and aging fighting phytonutrients and antioxidants such as Vitamin E.

-Hemp seeds also provide consumers with useful minerals, such as iron, zinc, calcium, phosphorous, and magnesium.

About MarijuanaStocks.com

MarijuanaStocks.com is the #1 online destination for anything and everything marijuana finance related. Whether you’re looking for the best marijuana stocks to buy, marijuana political news, trends and articles within the cannabis industry and so much more, MarijuanaStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Marijuana Stock News as well as cannabis industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to and enjoy.

About Cheryl Shuman

With about 25 years of experience, Cheryl Shuman has become known as the “Martha Stewart of Marijuana.” Her success using medical cannabis led her to found the Beverly Hills Cannabis Club (http://www.BHCClub.com). Today, Cheryl is the most visible and recognizable entrepreneurs in the marijuana reform movement, recently receiving the 2013 Activist of the Year Award at Seattle Hempfest.

Cheryl has reached over 100 million viewers worldwide while appearing on such mainstream shows as CNN’s Piers Morgan Live, The Katie Couric Show, The View, ABC’s 20/20, Good Morning America, Fox Business News and many other media outlets.

Cheryl now manages a $100 million funding facility to invest in the cannabis sector as well as personal endorsement contracts with ancillary products in the cannabis industry. In a short time, Cheryl has secured product placements for products in FX’s Wilfred, CBS News, The New Ricki Lake Show, and more. Shuman lectures internationally about everything from seed to sale of the Cannabis Plant and is currently working with the prestigious William Morris Endeavor Agency in Beverly Hills for film, television, book and lecturing deals. She also serves as Senior Advisor with Investment Bankers Jacobs Securities $50 million fund to invest in to the cannabis industry.

For more information, please visit http://www.CherylShuman.com.

Contact Information:

www.marijuanastocks.com
800-539-4313
pr@marijuanastocks.com

www.CherylShuman.com
Cheryl@CherylShuman.com
310.779.4797

SOURCE: MarijuanaStocks.com

ReleaseID: 430230

SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2015 / Christian (Chris) Frederiksen, Bay Area CPA, business advisor, author and highly regarded international lecturer received an honorary Ph.D. from his alma mater, Golden Gate University, at the commencement exercises in San Francisco on Friday, May 1, 2015.

Chris graduated from Golden Gate University in 1966 when the school was located in the YMCA building on Golden Gate Avenue. In his acceptance speech, he related how the beginning accounting classes were small and taught on the ground floor immediately below the weight-lifting room. “The regular sound of dropped barbells kept all the students awake,” stated Frederiksen.

After graduating from Golden Gate University, he won the John F. Forbes medal for the highest CPA exam score in California. Always grateful to his alma mater, he joined the adjunct faculty. He later joined Touche Ross and Co. in 1969 and by 1973 became one of the youngest partners in the firm. Leaving Touche Ross, he founded several Bay Area firms including his current firm Frederiksen-Crawford CPA, Inc.

Chris lectures and conducts seminars around the world with the 2020 Group USA, the world’s largest membership organization for smaller CPA firms which he co-founded in 2000. The 2020 Group now has offices on five continents.

Other professional accomplishments and honors are his being named as one of the 100 most important people in the Accounting profession by Accounting Today and being inducted into the Accountant’s Hall of Fame. He has written several business books including his latest 57 Ways to Grow Your Business.

Being passionate about education and particularly Golden Gate University, Chris states, “I arrived in America as an immigrant from England with little money and barely a high school diploma. Thanks to Golden Gate University, I was able to work and go to school. I have achieved everything I could have ever wanted. I have truly lived the American Dream.”

If you are interested in more information about Chris Frederiksen visit: http://2020groupusa.com or email Heidi Wilson at heidi@2020groupusa.com or call (800) 788-0190.

# # #

About the 2020 Group USA:

2020 Group USA is a membership group for accountants. We provide professional education, management consulting services and resources to accountants.

SOURCE: 2020 Group USA

ReleaseID: 430214

VANCOUVER, BC / ACCESSWIRE / June 29, 2015 / Discovery Harbour Resources Corp. (TSXV: DHR) (“DHR”) is pleased to announce that it has completed its Phase II drilling program at its 100% owned 2BAR Project in the Table Mountain Mining District, Churchill County, Nevada. During this campaign, the Company drilled 6 holes for a total of 1,567.4 feet of HQ core. The program was completed without injury or incident.

The analysis of the samples will be performed at ALS Global using standard preparations for rock samples. All samples will be analyzed using ALS Global’s four acid digestion followed by analysis using their ICP-MS process, code # ME-MS61 (48 element) and their Au-ICP 22, a 50 gram, FA, ICP-AES finish process for gold. All core samples were logged onsite, halved (cut), collected, bagged, labeled and hand-delivered to ALS in Reno through a secure chain of custody process which was overseen and directed by DHR’s QPs. Assay results are expected within 4 weeks.

Michael J. Senn, a licensed professional geologist, is the Qualified Person for Discovery Harbour Resources as described in National Instrument 43-101 and has reviewed and approved the technical contents of this release.

For further information, contact Kieran Magee by telephone at (778) 945-2958 or by email at kieran@discoveryharbour.com.

ON BEHALF OF THE BOARD OF DISCOVERY HARBOUR RESOURCES CORP.

“Bruno Hegner“

Frank D. Hegner
President, CEO, and Director

Disclaimer for Forward-Looking Information

Certain information regarding the Company contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, opinions, forecasts, projections or other statements that are not statements of fact.  Although the Company believes that expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.  The Company cautions that actual performance will be affected by a number of factors, many of which are beyond the Company’s control, and that future events and results may vary substantially from what the Company currently foresees. 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Discovery Harbour Resources Corp. 

ReleaseID: 430229

NEW YORK, NY / ACCESSWIRE / June 29, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of M Pharmaceutical, Inc. (CSX: MQ; OTCQB:MPHMF) with a price target of US$0.65/CAD$0.79.

The report is available here: MQ Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Based in Vancouver, Canada, M Pharma is a development stage biomedical company focused on developing solutions to improve the health and quality of life people suffering from obesity and diabetes. The company has exclusive rights to an innovative family of biomedical technologies including: 1) Trimeo weight loss capsules; 2) the Trimtec gastric management system, a intended to deliver a “realistic, patient centered” approach with reduced invasiveness; and 3) eMosquito, a wearable blood monitor that utilizes novel micro-electromechanical technology for automatic and autonomous monitoring of blood glucose levels. We see M Pharma as potentially being a hidden gem in the biotechnology sector. The company is a newly public entity with strong leadership and a novel portfolio of biomedical technologies targeting the large and growing global markets of morbid obesity and diabetes.

“The company has recently completed several key strategic actions in its corporate structure, including the appointment of industry pioneer Dr. Martin Mintchev as CEO, , three strategic acquisitions to fuel growth and development, and several impressive additions to its Board of Directors and Scientific Advisory Board,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of US$0.65 per share.”

Additional highlights from the report are as follows:

Large market opportunity targeting obesity and diabetes

We see tremendous potential for M Pharma if it can successfully develop and achieve clearance for its promising family of biomedical technologies. The company is targeting the large and growing multi-billion dollar markets of obesity and diabetes. Indeed, global weight management market is expected to rise from $148.1Bn in 2014 to $206.4Bn in 2019E, representing a compound annual growth rate of 6.9%. Similarly, Frost & Sullivan has estimated the global market for blood glucose products to be $8.67Bn per year.

New public company building momentum in healthcare

After becoming a public company through a merger transaction with First Sahara Energy, Inc. in February 2015, M Pharma has wasted little time building product momentum and articulating a compelling approach for managing obesity and diabetes. The company recently completed several key strategic actions in its corporate structure, including the completion of a 10:1 share consolidation to bring shares outstanding more in line with peers and finalizing three strategic acquisitions to fuel growth and development. Currently, M Pharma shares trade on the CSX, and we were pleased to see that the company announced on June 15, 2015, that it was granted approval to trade on the OTCQB under the ticker MPHMF. We see this as a nice development that will expand the company’s potential institutional shareholder base.

Impressive leadership team taking place

Given that M Pharma is a development stage enterprise targeting a large potential market, we view its management team as core to any investment thesis. We were pleased to see that M Pharma announced that medical technology pioneer Dr. Martin Mintchev accepted the position as President and CEO on April 15, 2015. Dr. Mintchev brings a wealth of industry expertise and leadership experience to the company, as well as a deep understanding of M Pharma’s innovative family of biomedical technologies. Indeed, Mintchev was the primary developer of the medical technologies held by M Pharma. We were also impressed to see the addition of Douglas Janzen to M Pharma’s Scientific Advisory Board. Janzen is co-founder and managing partner of Northview Ventures and has completed over $1bn in equity financing and over $1bn in licensing deals in the biotechnology sector. He is also CEO of Aequus Pharmaceuticals (TSXV: AQS) and a director of Neovasc Inc. (NASDAQ: NVCN).

Initiate coverage with a price target of US $0.65/CAD$0.79

Our analysis indicates a fair value estimate of CAD $0.79 (USD $0.65) per share, implying an upside of 315.8% from the recent price of $0.19. We view M Pharma as an intriguing high risk / high reward investment targeting a large and growing segment of the healthcare industry.

Please review important disclosures on our website at www.seethruequity.com.

About M Pharmaceutical, Inc.

M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has or has agreed to acquire the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of eMosquito, Trimeo and Trimtec biomedical technologies will require successful coordination and execution of a wide variety of technology disciplines.

The “Better Health. Better Life.” mantra and Circle of Life corporate identity is now online at www.m-pharma.ca.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 430224

HOUSTON, TX / ACCESSWIRE / June 29, 2015 / The One World Doll Project, a subsidiary of One World Holdings, Inc. (PINKSHEETS: OWOO), is excited to announce that Hallmark Stores has placed an initial order for the Prettie Girls!(TM) Tween Scene multicultural fashion and play dolls. This order stems from a preliminary outreach to the company by the Hallmark buying team. The One World Doll Project is confident that placement of these dolls this Holiday season within in Hallmark Stores across the country will further maximize exposure of the Prettie Girls! brand.

“As we continue to see a significant increase in product sales, this new business relationship with Hallmark Stores represents another component of our 2015 growth plan,” stated Trey Waldhauser, VP of Sales at The One World Doll Project.

About The One World Doll Project:

Established in 2010 by Trent T. Daniel and Stacey McBride-Irby, The One World Doll Project is committed to changing the retail landscape of the doll industry. The Prettie Girls!(TM), are a collection of fashion play dolls diverse in culture, interests, and style. McBride-Irby, former Mattel(R) designer most notably known as creator of the So In Style(R) dolls (the first African-American dolls by Mattel), designed the Prettie Girls! as unique works of art for a growing market yearning for something new to experience. The Prettie Girls! capture the essence of positive values and attributes that every little girl can embrace. “Prettie” stands for P(ositive) R(espectful) E(nthusiastic) T(ruthful) T(alented) I(nspiring) E(xcellent). Styled for play, yet filled with soul, The Prettie Girls! set new, higher, values-based standards for beauty- positive goals that reach across the globe and up for the stars!

More information about Stacey McBride-Irby, Trent T. Daniel, and The One World Doll Project, can be found at www.oneworlddolls.com.

Notice Regarding Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above; and the Company expressly disclaims responsibility to update the information included herein for events occurring after the date hereof.

Contact:

For investor relations,
One World Holdings, Inc.
ir@oneworlddolls.com
(281) 497-1311

SOURCE: One World Holdings, Inc.

ReleaseID: 430217

Focused on Increasing Awareness and Enhancing Shareholder Value

BOULDER, CO / ACCESSWIRE / June 29, 2015 / CLS Holdings USA, Inc. (OTC Markets: CLSH), a diversified cannabis company, today announced that it has retained Hayden IR. Hayden IR is a fifteen-year old, highly-recognized national investor relations firm that will raise CLS Holdings USA’s visibility and strengthen its relationships with the investment community, increase awareness and enhance shareholder value.

CLS Holdings USA business model includes licensing operations, processing revenue, processing facilities, sale of products and brand creation and consulting services. CLS stands for “Cannabis Life Sciences,” as it maintains a proprietary method of extracting various cannabinoids from the marijuana plant and converting them into higher quality and quantity. The Company mission is to be the industry leader in the extraction, conversion and marketing of cannabinoid oils, wax, edibles and shatter by leveraging our extraction methods and conversion processes.

“Over the past year, our CLS Holdings USA team has successfully taken a vision, implemented a business plan and created an infrastructure in the rapidly moving legalized cannabis industry. Our company is entering a very exciting phase as we look to commercialize our proprietary methods in a compliant, tested and standardized environment. We are excited by our progress to-date as we look to take advantage of the emerging legalized cannabis industry in which the market is projected to grow annually by 27% over the next three years to an expected market value greater than $8B by the end of 2018,” said Jeff Binder, CLS Holdings USA’s Chairman, President and Chief Executive Officer. “We believe it is an appropriate time to retain a national investor relations firm to help us target and expand our investor audience and ensure we are communicating effectively with Wall Street. We look forward to working with the team of professionals at Hayden IR to execute this important goal.”

With offices in New York, Phoenix, Minneapolis and San Diego, Hayden IR provides a comprehensive range of investor relations services. Hayden IR connects emerging growth companies with institutions, independent portfolio managers, buy-side and sell-side analysts, family offices, retail brokerage firms and accredited individual investors though a comprehensive, multi-tier proactive program. Hayden delivers expertise and professionalism in such areas as investor management, relationship building, awareness campaigns, online presence and corporate identity.

Brett Maas, Managing Partner at Hayden IR, added, “We are very excited to be working with CLS Holdings USA, a company with experienced management, proprietary methodology and strong relationships in the burgeoning regulated cannabis industry. Its business model, partnerships and industry relationships make CLS Holdings USA well positioned to take advantage of the expected growth of regulated cannabis over the next few years. The team at Hayden IR looks forward to articulating this opportunity to the professional investment community.”

About CLS Holdings USA, Inc.

CLS Holdings USA, Inc. is a diversified cannabis company, specializing in the extraction and conversion of cannabinoids. CLS stands for “Cannabis Life Sciences,” as it maintains a proprietary method of extracting various cannabinoids from the marijuana plant and converting them into higher quality and quantity. CLS Holdings USA business model includes licensing operations, processing revenue, processing facilities, sale of products and brand creation and consulting services.

For more information, check out: http://www.clsholdingsinc.com

Forward-Looking Statements

Forward-Looking Statements. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Form 8-K filed on April 30, 2015, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at http://www.sec.gov.

Contact Information

Corporate:
Chairman and CEO
Jeff Binder
jeff@clsholdingsinc.com
888-438-9132

Investors:
Hayden IR
Brett Maas
brett@haydenir.com
646-536-7331

SOURCE: CLS Holdings USA, Inc.

ReleaseID: 430228

WHITEFISH, MT / ACCESSWIRE / June 29, 2015 / Small-cap biotech stocks have been
top performers so far this year, with the PowerShares S&P SmallCap
Healthcare ETF (NASDAQ: PSCH) returning 25%, which is 5x better than the SPDR
S&P 500 ETF’s (NYSE: SPY) 5% return. Investors may want to consider adding
exposure to this asset class given its outperformance and lower correlation
with the overall U.S. equity market.

In this article, we’ll take a look
at three micro-cap and small-cap companies that are taking a different approach
to the status quo within multi-billion dollar industries.

eBalance Technology

Diabetes, a disorder of blood sugar
metabolism, is a prevalent and serious disease of major public health importance. Currently
there are approximately 387 million people in the world living with
diabetes with an expected increase to nearly 600 million by 2035. Diabetes has major adverse effects on people’s
health, but also presents a large economic burden. Global healthcare expenditures on diabetes
currently exceeds $420B. Experts agree
that a significant portion of the morbidity, mortality and cost of diabetes
could be avoided with improved control of blood sugars.

Cell MedX Corp. (OTC: CMXC) has
discovered a potentially valuable new, proprietary technology for the treatment
of diabetes – one that encompasses electrical micro-currents delivered in
distinctive patterns of waveform, amplitude, frequency, and duration leading to
alterations in metabolic pathways which may result in improved blood sugar
control. The treatment is believed to be of exceptionally low risk, and can be
self administered at home. It is a
uniquely new category of treatment.

In a pilot clinical discovery phase
trial in two diabetic subjects, the company
found that its e-Balance technology increased sensitivity to insulin and
up-regulated glycolytic processes, with subjects demonstrating enhanced glucose
utilization.

Further explorations of these
pathways will continue, along with endpoints like HbA1C, in an expanded
clinical trial that is currently recruiting subjects in Newport Beach, CA.

Investors in Cell MedX can look
forward to multiple potential catalysts in the near future including a series
of clinical trials, expanded basic research, intellectual property pursuits,
exploration of new form factors with innovative industrial designs, and growth
and expansion of the enterprise as their technology is productized and readied
for introduction into a global market.

BACcel Platform

Drug resistant organisms and
hospital-acquired infections have become an enormous global problem, especially
given the lack of new antibiotics capable of fighting these serious infections.
According to the CDC, one in five hospital patients has at lest one
healthcare-associated infection. Accelerated Diagnostics Inc. (NASDAQ: AXDX)
aims to rapidly identify these pathogens for treatment.

While traditional testing to
determine a pathogen’s susceptibility to a certain antibiotic may take upwards
of 50 hours, which is often too late to help patients, the company’s BACcel
platform is capable of performing the analysis in just three steps taking less
than five hours to complete. These tests have 98% sensitivity (identification
of target) and 97% specificity (identification of non-target).

The company plans on launching its
Accelerate ID/AST System in the U.S. in early 2016, after having initiated its
BSI trial and secured a CE Mark in mid-2015. Over the long-term, the company
could capture a significant piece of the $7.5 billion (estimated 2019) market
with peak gross margins of over 70% – an attractive proposition for investors
in the biotechnology space.

Cell-in-a-Box(R) Technology

Pancreatic cancer is one of the deadliest forms
of cancer, with less than half of patients surviving more than a year. In
addition to the diseases rapid progression, many patients experience unbearable
and, unfortunately, untreatable pain from malignant fluid (known as ascites) in
the abdominal cavity. PharmaCyte Biotech
Inc. (OTC: PMCB) is attempting to combat both the cancer and its side effects.

Rather than injecting patients with
high doses of toxic chemotherapy drugs, the company’s approach is to place its
Cell-in-a-Box(R) ifosamide-activating capsules in close proximity to the tumor
and then intravenously inject low doses of ifosamide – a cancer-killing drug – to attack the tumor. Unlike other approaches, there’s no immune response or
damage to tissue near where the capsules are placed.

The company has demonstrated the
effectiveness of the low dosage (as opposed to regular dosages that harms the
body) in two early clinical trials and is preparing to conduct a more advanced
Phase 2b clinical trial in the near future. Early evidence also suggests that the treatment may be effective in
delaying the accumulation of ascites fluid in mice bearing an aggressive form
of ovarian cancer.

Key Takeaway Points

Small-cap biotech stocks have been
top performers so far this year and they don’t seem to be ready to stop anytime
soon. Investors looking for exposure to the industry may want to consider
small-cap opportunities in the space, such as the three companies discussed in
this article, which are targeting multi-billion dollar industries with platform
technologies.

Click To
Sign Up For Future Email Updates On CellMedX Corp.
 http://www.tdmfinancial.com/emailassets/cmxc/cmxc_landing.php

Legal Disclaimer:

Except
for the historical information presented herein, matters discussed in this
release contain forward-looking statements that are subject to certain risks
and uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Emerging Growth LLC is not registered with any financial or
securities regulatory authority, and does not provide nor claims to provide
investment advice or recommendations to readers of this release. Emerging
Growth LLC may from time to time have a position in the securities mentioned
herein and may increase or decrease such positions without notice. For making
specific investment decisions, readers should seek their own advice. Emerging
Growth LLC may be compensated for its services in the form of cash-based
compensation or equity securities in the companies it writes about, or a
combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

SOURCE: Emerging Growth LLC

ReleaseID: 430227